COMP <GO>
PRCT vs BVS // REVENUE GROWTH (YOY)
PROCEPT BioRobotics Corporation (NASDAQ) VS. Bioventus Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: PRCT 3
— BVS 7
▲ REVENUE GROWTH (YOY) LEADER: PRCT
LAST: $20.30 (+0.50%) • MKT CAP: $1.16B
revenue-growth
37.20%
LAST: $14.87 (+1.50%) • MKT CAP: $1.25B
revenue-growth
-0.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRCT VS. BVS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRCT | BVS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 63.70% | 68.30% | -4.60 | BVS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 10.40% | -45.40 | BVS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 26.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.02% | 5.77% | -10.79 | BVS | /fcf-yield <GO> |
| Operating Margin | -33.70% | 9.50% | -43.20 | BVS | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 4.00% | -4.00 | BVS | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 37.20% | -0.90% | +38.10 | PRCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.98 | 2.25 | +1.73 | PRCT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | BVS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.7 | 43.9 | +6.78 | PRCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 51.2x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.16B | $1.25B | -$87.8M | BVS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRCT REV | BVS REV | PRCT GROSS % | BVS GROSS % | PRCT FCF | BVS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $308.1M | $568.1M | 63.7% | 68.3% | -$58.3M | $72.1M |
| FY 2024 | $224.5M | $573.3M | 61.1% | 67.7% | -$103.6M | $37.8M |
| FY 2023 | $136.2M | $512.3M | — | — | -$108.0M | $15.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRCT // BETA —
BVS // BETA —